Excalibur Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $471K | Sell |
12,254
-122
| -1% | -$4.69K | 0.18% | 106 |
|
|
2025
Q1 | $479K | Buy |
12,376
+195
| +2% | +$7.55K | 0.19% | 102 |
|
|
2024
Q4 | $412K | Sell |
12,181
-328
| -3% | -$11.1K | 0.16% | 111 |
|
|
2024
Q3 | $511K | Sell |
12,509
-252
| -2% | -$10.3K | 0.2% | 99 |
|
|
2024
Q2 | $491K | Buy |
12,761
+130
| +1% | +$5.01K | 0.2% | 99 |
|
|
2024
Q1 | $541K | Buy |
12,631
+100
| +0.8% | +$4.29K | 0.23% | 93 |
|
|
2023
Q4 | $468K | Sell |
12,531
-119
| -0.9% | -$4.44K | 0.22% | 95 |
|
|
2023
Q3 | $459K | Sell |
12,650
-60
| -0.5% | -$2.18K | 0.24% | 95 |
|
|
2023
Q2 | $453K | Sell |
12,710
-480
| -4% | -$17.1K | 0.23% | 94 |
|
|
2023
Q1 | $469K | Buy |
13,190
+90
| +0.7% | +$3.2K | 0.24% | 93 |
|
|
2022
Q4 | $460K | Sell |
13,100
-48
| -0.4% | -$1.69K | 0.24% | 96 |
|
|
2022
Q3 | $387K | Buy |
13,148
+2,302
| +21% | +$67.8K | 0.22% | 96 |
|
|
2022
Q2 | $590K | Sell |
10,846
-240
| -2% | -$13.1K | 0.31% | 76 |
|
|
2022
Q1 | $604K | Sell |
11,086
-14
| -0.1% | -$763 | 0.26% | 82 |
|
|
2021
Q4 | $612K | Sell |
11,100
-234
| -2% | -$12.9K | 0.25% | 92 |
|
|
2021
Q3 | $541K | Buy |
11,334
+224
| +2% | +$10.7K | 0.24% | 93 |
|
|
2021
Q2 | $553K | Buy |
11,110
+260
| +2% | +$12.9K | 0.25% | 88 |
|
|
2021
Q1 | $484K | Buy |
10,850
+3,632
| +50% | +$162K | 0.24% | 88 |
|
|
2020
Q4 | $332K | Buy |
7,218
+510
| +8% | +$23.5K | 0.18% | 108 |
|
|
2020
Q3 | $316K | Buy |
6,708
+504
| +8% | +$23.7K | 0.19% | 97 |
|
|
2020
Q2 | $316K | Buy |
6,204
+256
| +4% | +$13K | 0.21% | 84 |
|
|
2020
Q1 | $282K | Sell |
5,948
-112
| -2% | -$5.31K | 0.22% | 83 |
|
|
2019
Q4 | $356K | Buy |
+6,060
| New | +$356K | 0.23% | 76 |
|